Patients are Sutro’s
passion and purpose.

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. 

Our Sutro Story

Science designed to deliver ENDLESS OPPORTUNITY

Enabling a future where more is POSSIBLE.

Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience.

Explore opportunities

Join us and thrive in a team that values diversity and collaboration.

INVESTOR RESOURCES

NASDAQ: STRO

Stock Symbol

Press Releases

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., January 7, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established First-in-class Cell-free Capabilities at Commercial Scale

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established First-in-class Cell-free Capabilities at Commercial Scale SOUTH SAN FRANCISCO, Calif., January 7, 2025 – Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that...

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer – 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the...